VitalAire presented the first results of the project REPOCA in the II International Symposium on “COPD and smoking” which took place in Caceres on 10 and 11 November.

Currently, COPD (obstructive Chronic pulmonary disease) affects more than 210 million people and represents the 4th cause of death globally, providing that it becomes the 3rd in 2030.

Currently, around more than one million and a half people are treated for this disease in Spain, of which between 20-30% are frecuentadores sick. In words of Javier González Cappa, VitalAire boasts more than 30 years of experience that have served to check the effectiveness of the treatment of COPD is a good patient education, as well as the need to monitor and to share with doctors and public administrations compliance ”.

The service developed by VitalAire, REPOCA, is aimed at frecuentadores COPD patients, i.e., aimed at those who do not need even external inputs of oxygen, because they are frequent acute episodes and admissions that impair their quality of life and its environment. This project is aimed at strengthening the education of the patient in the management of COPD symptoms and thus improve as much as possible, their quality of life.

REPOCA was born with the desire to give efficient answers to patients, showing them how to control the previous signs of the disease and thus avoid income increased their quality of life and, most likely, their prospects for survival.

The II International Symposium COPD and smoking: diagnóstico-terapéutica update and future prospects ” has been designed to any healthcare professional interested in tackling smoking or COPD.

Air Liquide is the world leader in gases for industry, health and the environment and is present in 80 countries with 43,360 employees. Oxygen, nitrogen, hydrogen and the noble gases are at the heart of the activity of Air Liquide since its creation in 1902. From these molecules, Air Liquide continually reinvents its business to anticipate the challenges of their present and future markets. The Group innovates to enable progress, at the time that excels in jointly achieving dynamic growth and regularity in its results
innovative technologies for limiting emissions, reduce energy consumption in industry, put in value natural resources or develop the energies of tomorrow, such as hydrogen, biofuels and photovoltaics … oxygen for hospitals, home care, contribute to the fight against nosocomial diseases … Air Liquide combines numerous products with various technologies to develop applications and services with high added value for its clients and society.

A partner for the long term. The Group relies on the commitment of its employees, the confidence of its customers and the support of its shareholders to develop a long-term focus on competitive growth vision. The diversity of its teams, activities, markets and geographical presence ensures the soundness and sustainability of their development, and strengthens its ability to continuously conquer new territories to overcome its own boundaries, and build their future.

Air Liquide explores the best that the air can offer to preserve life, maintaining a dynamic of sustainable development. In 2010, its turnover reached 13,500 million EUR of which more than 80% out of France. Air Liquide is listed on the stock exchange of Euronext Paris (compartment A) and part of the CAC indexes 40 et Dow Jones Euro Stoxx 50.